Indolepropionic acid
Research stageAlso known as 1H-Indole-3-propionic acid, 3-(3-Indole)propionic acid, 3-(3-Indolyl)propanoic acid, 3-(3-Indolyl)propionic acid+5 more
1H-Indole-3-propionic acid, 3-(3-Indole)propionic acid, 3-(3-Indolyl)propanoic acid, 3-(3-Indolyl)propionic acid, 3-(Indol-3-yl)propionic acid, 3-indolepropionic acid, beta-Indolylpropionate, Indole-3-propionic acid, Indolylpropionic acid.
Recent clinical, regulatory, research and industry developments relating to this drug.
Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Nature communications1
- Nature microbiology1
- Brinck JE1
- Cadenas E1
- Chu C1
- Dai X1
- Hjørne AP1
- Hui Y1
- Jin X1
- Lan L1
- University of Copenhagen2
- BGI Institute of Applied Agriculture1
- Center for Innovation in Brain Science and Department of Pharmacology1
- Chalmers University of Technology1
- College of Food Science and Engineering1
- National Food Institute1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Indolepropionic acid in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature